CytomX Therapeutics CTMX Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's unrealized gains (losses) on available-for-sale securities?
- CytomX Therapeutics (CTMX) reported unrealized gains (losses) on available-for-sale securities of -$9K in Q1 2026.
- How has CytomX Therapeutics's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- CytomX Therapeutics's unrealized gains (losses) on available-for-sale securities increased by 67.9% year-over-year, from -$28K to -$9K.
- What is the long-term trend for CytomX Therapeutics's unrealized gains (losses) on available-for-sale securities?
- Over 4 years (2021 to 2025), CytomX Therapeutics's unrealized gains (losses) on available-for-sale securities has grown at a -19.0% compound annual growth rate (CAGR), from -$195K to $84K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric tracks the change in the fair value of investment securities classified as available-for-sale that has not yet been realized through a sale. It captures fluctuations in the market value of the company's liquid investment portfolio due to interest rate changes or market volatility. This provides insight into the unrealized gains or losses on the company's treasury assets held outside of core operations.